Iptacopan

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Atypical Hemolytic Uremic Syndrome

Conditions

Atypical Hemolytic Uremic Syndrome

Trial Timeline

Feb 28, 2024 → Jul 19, 2029

NCT ID

NCT05935215

About Iptacopan

Iptacopan is a phase 3 stage product being developed by Novartis for Atypical Hemolytic Uremic Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05935215. Target conditions include Atypical Hemolytic Uremic Syndrome.

What happened to similar drugs?

1 of 7 similar drugs in Atypical Hemolytic Uremic Syndrome were approved

Approved (1) Terminated (0) Active (6)

🔄CrovalimabChugai PharmaceuticalPhase 3

✅DuloxetineEli LillyApproved

🔄Teriparatide 20 mcgEli LillyPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄IptacopanNovartisPhase 3

🔄Iptcaopan 200 mgNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05222412	Pre-clinical	Active	—	—	C3 Glomerulopathy (C3G)
NCT06994845	Phase 3	Recruiting	Nov 27, 2025	Jun 30, 2030	Primary Immunoglobulin A Nephropathy (IgAN)
NCT06903234	Pre-clinical	Active	Mar 31, 2025	Oct 1, 2029	Hemoglobinuria, Paroxysmal
NCT06797518	Phase 2	Recruiting	Feb 21, 2025	Nov 27, 2027	Glomerulonephritis, IGA
NCT06517758	Phase 3	Recruiting	Jul 31, 2024	May 27, 2032	Generalized Myasthenia Gravis
NCT05935215	Phase 3	Recruiting	Feb 28, 2024	Jul 19, 2029	Atypical Hemolytic Uremic Syndrome
NCT05630001	Phase 3	Completed	Apr 24, 2023	Oct 17, 2024	Paroxysmal Nocturnal Hemoglobinuria
NCT04889430	Phase 3	Active	Jan 17, 2022	Aug 13, 2026	Atypical Hemolytic Uremic Syndrome
NCT05086744	Phase 2	Terminated	Dec 21, 2021	May 17, 2024	Immune Thrombocytopenia (ITP)
NCT04747613	Phase 3	Active	Jul 27, 2021	Oct 19, 2027	Paroxysmal Nocturnal Hemoglobinuria
NCT03439839	Phase 2	Completed	Apr 9, 2018	Feb 28, 2022	Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Competing Products

18 competing products in Atypical Hemolytic Uremic Syndrome

See all competitors

Product	Company	Stage	Hype Score
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Duloxetine	Eli Lilly	Approved	43
Teriparatide 20 mcg	Eli Lilly	Phase 3	40
Baricitinib	Eli Lilly	Pre-clinical	26
Ravulizumab	AstraZeneca	Pre-clinical	33
Eculizumab	AstraZeneca	Phase 3	40
Iptacopan	Novartis	Phase 3	44
Iptcaopan 200 mg	Novartis	Phase 3	47
Ropeginterferon Alfa-2B	PharmaEssentia	Phase 2	42
CCX168	Amgen	Phase 2	27
Tazemetostat + Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 1/2	39
Cemdisiran	Alnylam Pharmaceuticals	Phase 2	24
cemdisiran + Placebos	Alnylam Pharmaceuticals	Phase 2	24
Axatilimab + Azacitidine	Incyte	Phase 1/2	36
Gemcitabine + Paxalisib	Pacific Biosciences	Phase 2	32
Apatinib Mesylate	Brain Biotech	Pre-clinical	23
azurin-derived cell-penetrating peptide p28	Brain Biotech	Phase 1	19